Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast
Pfizer and Merck KGaA have hit the trifecta for PD-L1 failure in ovarian cancer.
The two partners said late today that they are shuttering …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
